Teladoc Health Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
TDOC$8.94-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveGain (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances as of December 31, 2021 | 160,469,325 | $160 | $17,473,336 | $(1,421,454) | $(6,285) | $16,045,757 |
| Cumulative effect adjustment due to adoption of ASU 2020-06 (see Note 2) | — | — | (363,731) | 72,698 | — | (291,033) |
| Exercise of stock options | 591,213 | 1 | 5,883 | — | — | 5,884 |
| Issuance of common stock upon vesting of restricted stock units | 1,508,570 | 2 | (2) | — | — | — |
| Issuance of stock under employee stock purchase plan | 271,159 | — | 7,064 | — | — | 7,064 |
| Issuance of common stock for 2025 Notes | 93 | — | 7 | — | — | 7 |
| Equity portion of extinguishment of 2025 Notes | — | — | (2) | — | — | (2) |
| Stock-based compensation | — | — | 236,090 | — | — | 236,090 |
| Other comprehensive loss, net of tax | — | — | — | — | (36,491) | (36,491) |
| Net loss | — | — | — | (13,659,531) | — | (13,659,531) |
| Balances as of December 31, 2022 | 162,840,360 | 163 | 17,358,645 | (15,008,287) | (42,776) | 2,307,745 |
| Exercise of stock options | 175,761 | — | 1,481 | — | — | 1,481 |
| Issuance of common stock upon vesting of restricted stock units | 3,049,824 | 3 | (3) | — | — | — |
| Issuance of stock under employee stock purchase plan | 592,308 | 1 | 10,439 | — | — | 10,440 |
| Stock-based compensation | — | — | 220,989 | — | — | 220,989 |
| Other comprehensive income, net of tax | — | — | — | — | 5,786 | 5,786 |
| Net loss | — | — | — | (220,368) | — | (220,368) |
| Balances as of December 31, 2023 | 166,658,253 | 167 | 17,591,551 | (15,228,655) | (36,990) | 2,326,073 |
| Exercise of stock options | 520,190 | — | 3,566 | — | — | 3,566 |
| Issuance of common stock upon vesting of restricted stock units | 5,634,883 | 6 | (6) | — | — | — |
| Issuance of stock under employee stock purchase plan | 591,690 | — | 5,409 | — | — | 5,409 |
| Stock-based compensation | — | — | 158,674 | — | — | 158,674 |
| Other comprehensive loss, net of tax | — | — | — | — | (1,398) | (1,398) |
| Net loss | — | — | — | (1,001,245) | — | (1,001,245) |
| Balances as of December 31, 2024 | 173,405,016 | $173 | $17,759,194 | $(16,229,900) | $(38,388) | $1,491,079 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.